SAN DIEGO, Calif.--(BUSINESS WIRE)--PURE Bioscience (NASDAQ: PURE) today announced the strengthening of its program to develop silver dihydrogen citrate (SDC)-based pharmaceutical products with the addition of a new development partner, FTA Therapeutics, LLC (FTA).
